Omni-Biotic Stress Release
Commercial- Indications
- Stress management, Anxiety
Company intelligence / Profile preview
Omni-Biotic
Graz, Styria, Austriaomnibioticlife.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Omni-Biotic offers clinically tested probiotic formulations with demonstrated efficacy for specific health outcomes. Their AB 10 formulation has shown success in eradicating recurrent Clostridium difficile and infections with gram-negative bacteria, as well as reducing antibiotic-associated diarrhea.
- Therapeutic areas
- GastroenterologyPsychiatryImmunologyInfectious Diseases
- Modalities
- Probiotic bacteria
- Industry
- Food & Nutrition
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Zuellig Pharma (for Asian market expansion)
Beyond the preview
Go deeper on Omni-Biotic.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Omni-Biotic.